2026-03-27 Eisai Co.,Ltd. “The European Medicines Agency has accepted the marketing authorization application for the anticancer drug taretrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer. This application will be reviewed for full approval according to the standard schedule. Applications are also planned in other licensed regions of Eisai, including the UK and Canada. Taretrectinib is already approved in the US, China, and Japan for the treatment of advanced ROS1-positive non-small cell lung cancer.”